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A report on the Epigenetic Engineering Meeting
hosted by the Barts Institute of Cancer, held in
London, UK, May 7, 2014presented compelling evidence to show that we can nowThis short and focused meeting was set up to bring the
audience up to date with a specific set of techniques
broadly categorized as epigenetic engineering (or epigen-
etic editing). The speakers reminded us of very important
questions that still linger, like Damocles’ sword, over the
field of epigenetics: what is the real role of epigenetics dur-
ing gene transcription and development? Are epigenetic
modifications the cause or consequence of these pro-
cesses? While the jury is still out, this meeting reminded
us that the tools needed to answer these philosophical
questions are finally available and improving by the hour.
Moreover, there was also a general consensus that epigen-
etic editing might provide the next big advance in cancer
treatment. Epigenetic-editing treatments might finally
allow targeted modulation of gene expression and could
bypass the side effects of current epigenetic drugs.Two thumbs down to epigenetics haters?
Epigenetics has been defined in several ways, but none of
these definitions includes an answer to the recurrent ques-
tion: what are the actual roles of epigenetic modifications?
With the explosion of ChIP-seq-based studies, we have
now gathered epigenetic information (DNA methylation
and histone modification maps) for hundreds of cell lines.
We know that there is a strong correlation between
certain epigenetic marks and the transcriptional status of
nearby genes. We also understand that epigenetic infor-
mation represents a sort of cellular barcode that is
constantly modified during differentiation, and probably
throughout cancer initiation and progression. Nevertheless,Correspondence: l.magnani@imperial.ac.uk
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months following its publication. After this tim
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and correlative, and as not offering any answers to the con-
sequentiality or temporal hierarchy between epigenetic and
transcriptional reprogramming.
Tomasz Jurkowski (University of Stuttgart, Germany)
begin to address this causality dilemma. He outlined
how his laboratory, like many others, is exploiting DNA-
targeting molecular machines, such as zinc fingers,
TALEN and Crispr-Cas9, fused with epigenetic modifiers
(for example, histone methyl-tranferases and de-acetylases).
The goal is to change the epigenetic information at specific
regulatory loci, such as enhancers and promoters, in order
to shut down or activate single genes. By fusing de novo
DNA methyl-tranferases (DNMT3) to small zinc-finger
effectors, Jurkowski and colleagues were able to target
EPCAM and VEGFA, two key genes involved in cancer
development. More importantly, they demonstrated that
adding the DNMT3 co-activator could accelerate the reac-
tion leading to a stronger repression. Interestingly, DNA
methylation was found to be highly directional and to re-
flect the topology of DNA-zinc finger interactions. It was
also noted that the number of methylated nucleotides was
consistently higher than expected. This phenomenon is
attributed to the cooperative binding of individual zinc
finger-DNMT3 fusion proteins and can be exploited to
increase the desired silencing effect.
DNA de-methylation was also the weapon of choice for
James Angstman (Massachusetts General Hospital, USA).
In Angstman’s work, the aim was to test how many CpG
sites must be de-methylated in order to re-activate gene
expression. The data derived from studying the β-globin
promoter suggested that not all CpG sites are equivalent
and introduced the idea of insulator CpGs, as opposed to
regulatory CpGs. Eric Miska (Gurdon Institute at the
University of Cambridge and the Wellcome Trust Sanger
Institute, UK) reminded the audience that the border
between epigenetics and genetics is far more labile than
expected. Using Caenorhabditis elegans, an organism
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mediated by a non-coding RNA mechanism (piwi-RNA).
Miska suggested that piwi-RNAs might be seen as the
‘guardian of the epigenome’, with an involvement in main-
taining retro-transposon silencing. Use of a different
worm that has DNA methylation abilities (Trichinella
spiralis) hinted at the possibility of RNA-directed DNA
methylation, a fascinating hypothesis for mammalian
genomics enthusiasts. Finally, Donna Bond (University of
Cambridge, UK) presented exciting data from the plant
kingdom. Using modified viruses, Bond and colleagues
were able to silence (via DNA methylation) single genes
epigenetically. The virus itself was not transmitted across
generations, but its silencing effects were carried out in
the pollen of infected plants and passed on to the new
generation.
These results are impressive and demonstrate how epi-
genetic editing can be effectively used to regulate the ex-
pression of single genes reversibly. A problem that has not
yet been overcome involves specificity: the zinc finger and
CrispR-Cas9 strategies have not yet reached single locus
specificity, but they still offer a major advancement com-
pared with the use of genome-wide epigenetic drugs such
as 5-azacytidine.
Histone marks and more
The other face of epigenetic editing deals with another
crucial component of epigenetic information: histone
modification. Since the seminal work of Allis and col-
leagues that formalized the theory of the histone code,
various laboratories have tried to draw a direct link be-
tween covalent tail modifications and transcription. David
Cano Rodriguez (University Medical Center Groningen,
The Netherlands) gave the audience two clear examples of
how we might use histone modifications to ‘wake the
sleeping beauties’ (tumor suppressors) and ‘silence the
screaming’ (oncogenes). Zinc fingers are extremely prom-
ising for this purpose as their chemistry is compatible with
in vivo usage. They also present several advantages as
tools for epigenetic editing when compared to small
interfering RNA (siRNA), cDNA or artificial transcription
factors. For example, epigenetic editing using zinc fingers
offers sustained and inheritable gene suppression without
the integration of foreign DNA or siRNA. On the other
hand, gene activation is regulated by the endogenous
environment and automatically induces the correct gene
isoform rather than leading to the non-physiological
expression of a pre-determined isoform.
Using zinc fingers fused with the catalytic subunit of
the PRC2 repressor complex, Rodriguez and colleagues
were able to methylate histone 3 specifically at the Neu/
Her2 gene. Her2 expression directly leads to drug resist-
ance in breast cancer and can only be targeted using
expensive monoclonal antibodies. The suppression ofthe Her2 gene was functional and led to a significant
reduction in cell proliferation. The transcriptional status
of Her2 was also manipulated in the opposite direction,
using a transcriptional activator to demonstrate the
specificity of zinc-finger targeting. Importantly, whereas
activation resulted in de novo deposition of some histone
marks, H3K9me3 induction was linked to a strong reduc-
tion of H3 acetylation and H3 lysine 4 tri-methylation.
These data once again highlight the complex relationship
between epigenetic information and transcription and
recommend caution when discussing the role of epigenetic
modifications in isolation.
Going the distance
A common thread among all of the work described at
this meeting was that all of the epigenetic editing was
conducted at promoter elements. This approach was
adopted to simplify interpretation of the results and to
draw a straight line between regulatory regions and the
regulated genes. This use of strategy, however, may also
explain why the observed changes in transcription were
often very subdued but very significant. It was proposed
that simultaneous targeting of promoters and associated
distal elements, such as enhancers, could dramatically
improve our ability to reprogram the epigenetic barcode
of cells. In the future, such strategies could lead to effi-
cient differentiation protocols for induced stem cells.
Equally important, we can envision a future in which
gene manipulation will not necessarily include only
genetically engineered intervention but could include a
‘softer’ and more versatile toolkit.
Clinical trials using zinc-finger epigenetic editing are
now in phase II for HIV/AIDS and Alzheimer's disease.
Studies such as those presented at this meeting let us
hope that more and more oncogenes or tumor suppres-
sors will be targeted effectively in the near future of
epigenomic medicine.
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